Consolidated Financial Statements

Justera Health Ltd. (formerly ScreenPro Security Inc.)

For the year ended December 31, 2023

(Expressed in Canadian dollars)



SHIM & Associates LLP Chartered Professional Accountants

Suite 900 – 777 Hornby Street Vancouver, B.C. V6Z 1S4 **T:** 604 559 3511 | **F:** 604 559 3501

INDEPENDENT AUDITOR'S REPORT

To the Shareholders of Justera Health Ltd. (formerly ScreenPro Security Inc.)

Opinion

We have audited the accompanying consolidated financial statements of Justera Health Ltd. (formerly ScreenPro Security Inc.) (the "Company"), which comprise the consolidated statements of financial position as at December 31, 2023 and 2022, and the consolidated statements of loss and comprehensive loss, changes in shareholders' equity (deficiency) and cash flows for the years then ended and notes to the consolidated financial statements, including material accounting policy information.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as at December 31, 2023 and 2022, and its consolidated financial performance and cash flows for the years then ended in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (IFRS).

Basis for Opinion

We conducted our audits in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Statements* section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the consolidated financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Material Uncertainty Related to Going Concern

We draw attention to Note 1 of the financial statements, which indicates that a material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern. Our opinion is not modified in respect of this matter.

Key Audit Matter

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements for the year ended December 31, 2023. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Impairment assessment of intangible assets and goodwill

As at December 31, 2023, the Company had finite-lived intangible assets of \$178,636 and goodwill of \$Nil.

Intangible assets with finite lives are assessed for any indications of impairment at the end of each reporting period. Indicators of impairment were identified for the intangible assets related to GoStop Inc. cash generating unit ("CGU"), Add Biomedical Inc. CGU and Justera Wellness Inc. CGU. The recoverable amounts for GoStop Inc. CGU, Add Biomedical Inc. CGU and Justera Wellness Inc. CGU were based on value in use using a discounted cash flow model. The significant assumptions applied by management in determining the value in use included revenue projections, revenue growth rate and discount rate. The recoverable amounts of GoStop CGU, AddBio CGU and Juillet CGU were below their respective carrying amounts and accordingly, an aggregate impairment charge of \$730,314 was recognized during the year ended December 31, 2023.

Goodwill is assessed for impairment annually, or more frequently if events and circumstances indicate that the carrying amount may be impaired. Management has performed its annual impairment test as at December 31, 2023. Management determined that the CGU for the purpose of testing impairment of goodwill is within the Company's subsidiary, Justera Wellness Inc., NatureVan Nutrition Ltd. and Triniti Trading Corporation.

The recoverable amount of the GoStop Inc. CGU, Add Biomedical Inc. CGU, NatureVan Nutrition Ltd. CGU, Justera Wellness Inc. CGU and Triniti Trading Corporation CGU was based on value in use using a discounted cash flow model. The significant assumptions applied by management in determining value in use included the revenue projections, a revenue growth rate and a discount rate. The recoverable amount of the GoStop Inc. CGU, Add Biomedical Inc. CGU, NatureVan Nutrition Ltd. CGU, Justera Wellness Inc. CGU and Triniti Trading Corporation CGU were below their respective carrying amounts and accordingly, an aggregate impairment charge on intangible assets of \$730,314 and goodwill of \$3,196,281 was recognized during the year ended December 31, 2023.

We considered this a key audit matter due to the judgment by management in determining the recoverable amounts, including the use of significant assumptions. This, in turn, led to a high degree of subjectivity and audit effort in performing procedures to test the significant assumptions.

Evaluating how management determined the recoverable amounts of the GoStop Inc. CGU, Add Biomedical Inc. CGU, NatureVan Nutrition Ltd. CGU, Justera Wellness Inc. CGU and Triniti Trading Corporation CGU, which included the following procedures:

- Reviewed management's assessment of CGUs
- Reviewed management's assessment of the indicators of impairment with respect to finite-lived intangible assets.
- Tested the appropriateness of the value in use methods used and the mathematical accuracy of the discounted cash flow models.
- Tested the reasonableness of the estimated cash flows by considering historical performance of the Company and the budget approved by management.
- Tested the underlying data and inputs used in the discounted cash flow models.

Accounting for the acquisition of Juillet Wellness Spa and Triniti Trading Corporation

During the year, the Company completed the acquisition of the following:

- Juillet Wellness Spa, by issuing common shares with a fair value of \$120,000 and assumed liabilities of \$450,000 as consideration.
- Triniti Trading Corporation, by paying cash of \$125,000 and issuing common shares with a fair value of \$101,500 as consideration.

In relation to the acquisition of Juillet Wellness Spa, management determined that the acquisition met the definition and criteria to be classified as a business combination. Accordingly, under IFRS 3, the Company measured the assets acquired and liabilities assumed at their estimated fair values. The difference between the fair value of cash and assumed liabilities recognized of \$570,000 and the fair value attributed to the identifiable net assets assumed resulted in goodwill of \$301,897.

In relation to the acquisition of Triniti Trading Corporation, management determined that the acquisition met the definition and criteria to be classified as a business combination. Accordingly, under IFRS 3, the Company measured the assets acquired and liabilities assumed at their estimated fair values. The difference between the fair value of cash and common shares recognized of \$226,500 and the fair value attributed to the identifiable net assets assumed resulted in goodwill of \$218,386.

We considered this a key audit matter due to the judgment applied by management in evaluating whether the acquisition constituted a business combination under IFRS 3 or an asset acquisition under IFRS 2. Management also applied judgment in assessing the completeness of identifiable assets and liabilities acquired and assumed including the unidentifiable goods and services. We also considered this a key audit matter due to the estimates applied by management in determining fair value of the identifiable assets acquired and liabilities assumed, including the use of significant assumptions. These considerations led to a high degree of subjectivity and audit effort in performing procedures to evaluate the judgments and test the significant assumptions.

Evaluating the judgments and estimates made by management in accounting for the acquisition of Juillet Wellness Spa and Triniti Trading Corporation, which included the following procedures:

- Reviewed the purchase agreements to obtain an understanding of the key terms and structure of the transaction.
- Assessed management's evaluation of whether the acquisition constituted a business combination under IFRS 3 or an asset acquisition under IFRS 2.
- Evaluated the valuation method used by management's external valuation specialist in determining fair value of the identifiable assets acquired, liabilities assumed, including intangible assets and goodwill.
- Recalculated the fair value of the consideration paid by the Company, identifiable assets acquired, liabilities assumed, including intangible assets and goodwill.

Other Information

Management is responsible for the other information. The other information comprises the information included in the Management's Discussion and Analysis.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information, and in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with IFRS, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

• Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate
 in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal
 control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and
 whether the consolidated financial statements represent the underlying transactions and events in a manner that
 achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

The engagement partner on the audit resulting in this independent auditor's report is Nicholas Koo.

"SHIM & Associates LLP"

Chartered Professional Accountants Vancouver, Canada May 21, 2024

(formerly ScreenPro Security Inc.) Consolidated Statements of Financial Position

(Expressed in Canadian Dollars)

	As at December 31,	As at December 31,
	2023 \$	2022 \$
ASSETS		
CURRENT	0.4.50	
Cash	94,693	437,415
Accounts receivable	948,076	74,398
Sales tax recoverable		8,079
Inventory [note 4]	97,943	462,079
Prepaid expenses	107,643	85,015
	1,248,355	1,066,986
DEPOSIT [note 8]	_	10,000
PROPERTY AND EQUIPMENT [note 5]	75,547	506,240
RIGHT-OF-USE ASSET [note 8]	169,244	119,464
INTANGIBLE ASSETS [note 6]	178,636	582,084
GOODWILL [note 6]	_	2,675,998
Total assets	1,671,782	4,960,772
LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT	1 729 756	2 554 404
Accounts payable and accrued liabilities	1,738,756	3,554,404
Current portion of lease liabilities [note 8]	85,350	79,484
LEAGE LIADILITIES (, , 0)	1,824,106	3,633,888
LEASE LIABILITIES [note 8]	189,050	41,180
LOAN PAYABLE [note 12]	60,000	_
DEFERRED TAX LIABILITY [note 13]	48,232	
Total liabilities	2,121,388	3,675,068
SHAREHOLDERS' EQUITY (DEFICIENCY)		
Share capital <i>[note 9]</i>	16,769,784	15,592,036
Options reserve	67,416	
Warrants reserve	2,142,182	2,142,182
Accumulated deficit	(19,428,988)	(16,448,514)
Total shareholders' equity (deficiency)	(449,606)	1,285,704
Total liabilities and shareholders' equity (deficiency)	1,671,782	4,960,772
Subsequent event (Note 16)	1,0 / 1,7 02	1,500,772
Subsequent event (1700e 10)		
Approved on behalf of the Board "Paul Haber"	"Youngcho	Lee"

The accompanying notes are an integral part of these consolidated financial statements

Director (Signed)

Director (Signed)

(formerly ScreenPro Security Inc.) Consolidated Statements of Loss and Comprehensive Loss

(Expressed in Canadian Dollars)

	For the year ended	For the year ended
	December 31, 2023 \$	December 31, 2022
	3	\$
SALES	1,914,103	14,692,628
COST OF SALES	(1,057,529)	(12,112,045)
GROSS PROFIT	856,574	2,580,583
EXPENSES		
Consulting fees [note 7]	1,307,111	2,087,990
Depreciation [notes 5, 6 and 8]	393,866	1,107,000
General and administrative [note 7]	1,056,303	1,057,415
Marketing	454,669	227,334
Professional services	459,612	376,614
Salaries [note 7]	946,352	1,642,787
Share-based payments	67,416	_
	4,685,329	6,499,140
LOSS BEFORE OTHER ITEMS	(3,828,755)	(3,918,557)
Gain on sale of fixed assets [note 5]	138,908	_
Gain on settlement [note 15]	4,888,625	_
Excess consideration paid over net assets acquired [note 12]	_	(1,333,225)
Impairment of intangible assets [note 6]	(730,314)	_
Impairment of goodwill [note 6]	(3,196,281)	_
Impairment of long-lived assets [notes 5 and 8]	(288,044)	_
Foreign currency exchange loss	(2,029)	_
Other income	18,667	_
Other expenses	(21,273)	
NET LOSS AND COMPREHENSIVE LOSS BEFORE INCOME TAXES	(3,020,496)	(5,251,782)
Deferred tax recovery [note 13]	40,022	(, , , , , , ,
Bolefied materials [note 13]	40,022	
NET LOSS AND COMPREHENSIVE LOSS	(2,980,474)	(5,251,782)
Basic and diluted loss per share	(0.02)	(0.06)
Weighted average		
number of common shares - basic and diluted	128,308,522	87,261,106

The accompanying notes are an integral part of these consolidated financial statements

(formerly ScreenPro Security Inc.) Consolidated Statements of Changes in Shareholders' Equity (Deficiency)

(Expressed in Canadian Dollars)

	Number of shares	Share capital	Options reserve	Warrants reserve \$	Accumulated deficit	Total \$
Balance, December 31, 2021	41,638,916	11,073,403	_	969,332	(11,196,732)	846,003
Units issued for acquisitions [notes 9 and 12]	58,833,331	3,895,833	_	881,850	_	4,777,683
Private placements [note 9]	18,300,000	624,000	_	291,000	_	915,000
Share issue costs	_	(1,200)	_	_	_	(1,200)
Net loss for the year					(5,251,782)	(5,251,782)
Balance, December 31, 2022	118,772,247	15,592,036	_	2,142,182	(16,448,514)	1,285,704
Shares issued for acquisitions [notes 9 and 12]	8,060,000	221,500	_	_	_	221,500
Private placements [note 9]	33,973,336	1,019,200	_	_	_	1,019,200
Share issue costs	_	(62,952)	_	_	_	(62,952)
Share-based payments	_	_	67,416	_	_	67,416
Net loss for the year					(2,980,474)	(2,980,474)
Balance, December 31, 2023	160,805,583	16,769,784	67,416	2,142,182	(19,428,988)	(449,606)

The accompanying notes are an integral part of these consolidated financial statements

(formerly ScreenPro Security Inc.) Consolidated Statements of Cash Flows

(Expressed in Canadian Dollars)

	For the year ended December 31, 2023	For the year ended December 31, 2022
OPERATING ACTIVITIES	*	
Net loss	(2,980,474)	(5,251,782)
Items not affecting cash:	(=,, = =,,)	(-,,,)
Accretion and interests	17,080	16,415
Depreciation	393,866	1,107,000
Gain on disposal of fixed assets	(138,908)	, , <u> </u>
Gain on settlement	(4,888,625)	_
Gain on termination of leases	(656)	_
Excess consideration paid over net assets acquired		1,333,225
Impairment of goodwill, intangibles, and fixed assets	4,214,639	, , <u> </u>
Loss on loan refinancing	20,000	_
Share-based payments	67,416	_
Changes in non-cash working capital balances:		
Accounts receivable	(503,827)	(11,852)
Harmonized sales tax recoverable	8,079	35,135
Inventory	394,136	1,974,869
Prepaid expenses	4,615	98,705
Accounts payable and accrued liabilities	2,618,766	(371,901)
Deferred tax liability	(40,022)	<u> </u>
Cash used in operating activities	(813,915)	(1,070,186)
INVESTING ACTIVITIES		
Acquisition of AddBio, net of cash received		1,069,776
Acquisition of NatureVan, net of cash received		(486,686)
Acquisition of Triniti, net of cash received	(124,101)	_
Purchase of property and equipment	(236,397)	(117,778)
Cash provided by (used in) investing activities	(360,498)	465,312
FINANCING ACTIVITIES		
Shares issued for cash, net of share issue costs	956,248	913,800
Lease payments	(124,557)	(79,300)
Cash provided by financing activities	831,691	834,500
INCREASE (DECREASE) IN CASH	(342,722)	229,626
CASH - BEGINNING OF YEAR	437,415	207,789
CASH - END OF YEAR	94,693	437,415
Supplementary cash flow information		
Interest income	_	_
Income tax paid	<u> </u>	<u> </u>

The accompanying notes are an integral part of these consolidated financial statements

Notes to Consolidated Financial Statements

For the years ended December 31, 2023 and 2022 (Expressed in Canadian Dollars)

1. NATURE OF BUSINESS

Justera Health Ltd. (formerly ScreenPro Security Inc.) (the "Company") is incorporated under the laws of the Province of Ontario. The Company's common shares are listed on the Canadian Securities Exchange under the trading symbol "VTAL".

While these consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") on a going concern basis that presumes the realization of assets and discharge of liabilities in the normal course of business, there are material uncertainties related to adverse conditions and events that cast significant doubt on the Company's ability to continue as a going concern.

During the year ended December 31, 2023, the Company incurred a loss of \$2,980,474 (2022 - \$5,251,782) and, as of that date, the Company had accumulated deficit of \$19,428,988 (2022 - \$16,448,514) and a working capital deficit of \$575,751 (2022 - \$2,566,902). The Company's continuing operations as intended are dependent upon its the ability to raise additional funds, investor sentiment and financial market conditions. Should the Company be unable to secure additional financing, the Company may be unable to discharge its net liabilities. These uncertainties may cast significant doubt upon the Company's ability to continue as a going concern.

The office address of the Company is 2300 Yonge Street, Suite 2802, Toronto, Ontario, M4P 1E4.

In March 2020, the World Health Organization declared a global pandemic related to the virus known as COVID-19. The Company's business began as a result of this pandemic. The Company's business related to COVID-19 has been declining since 2022, completely coming to an end in April 2023.

2. BASIS OF PRESENTATION

2.1 Basis of presentation and statement of compliance

These consolidated financial statements for the Company for the year ended December 31, 2023 have been prepared in accordance with IFRS, issued by the International Accounting Standards Board ("IASB").

These consolidated financial statements were approved and authorized for issuance by the Company's Board of Directors on May 21, 2024.

The consolidated financial statements are presented in Canadian dollars which is also the Company's functional currency. The consolidated financial statements are presented at historical costs, other than certain financial instruments measured at fair value. The accrual method of accounting is used in the consolidated financial statements, other than cash flow information. The accounting policies have been applied consistently in these consolidated financial statements, unless otherwise indicated.

Notes to Consolidated Financial Statements

For the years ended December 31, 2023 and 2022 (Expressed in Canadian Dollars)

2.2 Principles of consolidation

The Company's wholly owned operating subsidiaries include:

	Jurisdiction of		
Name of the entity	incorporation	Functional currency	Principal activity
ScreenPro Security Ltd. ("ScreenPro Ltd")	Canada	Canadian Dollar	Inactive
GoStop Inc. ("GoStop")	Canada	Canadian Dollar	Inactive
Justera Wellness Inc. (formerly Concierge Medical	Canada	Canadian Dollar	Health and wellness
Consultant Inc.) ("Justera")			
Add Biomedical Inc. ("AddBio")	Canada	Canadian Dollar	Health and wellness
NatureVan Nutrition Ltd. ("NatureVan")	Canada	Canadian Dollar	Health and wellness
Triniti Trading Corporation ("Triniti")	Canada	Canadian Dollar	Health and wellness

^{*} Triniti is consolidated from November 2023, being the acquisition date.

Intercompany balances and transactions are eliminated upon consolidation and preparation of these consolidated financial statements.

2.3 Basis of measurement

These consolidated financial statements have been prepared on the historical cost basis except for certain financial instruments, which are measured at fair value, as explained. The financial statements are presented in Canadian dollars which is the presentation and functional currency of the Company.

3. MATERIAL ACCOUNTING POLICIES

3.1 Cash

Cash represents amount deposited with the financial institution.

3.2 Property and equipment

Property and equipment are stated at cost less accumulated depreciation and impairment losses. The cost of an item of property and equipment consists of the purchase price, any costs directly attributable to bringing the asset to the location and condition necessary for its intended use and an initial estimate of the costs of dismantling and removing the item and restoring the site on which it is located. Property and equipment are depreciated at the following rates and methods:

Machinery
Vehicles
Leasehold improvements

3-year straight-line method 2-year straight-line method Straight-line over the lease term

Notes to Consolidated Financial Statements

For the years ended December 31, 2023 and 2022 (Expressed in Canadian Dollars)

Property and equipment acquired during the period but not placed into use are not depreciated until they are placed into use. All additions made during the period are depreciated from the date of purchase.

An item of property and equipment is derecognized upon disposal, when held for sale or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on disposal of the asset, determined as the difference between the net disposal proceeds and the carrying amount of the asset, is recognized in the statement of loss and comprehensive loss.

The Company conducts an annual assessment of the residual balances, useful lives and depreciation methods being used for property and equipment and any changes arising from the assessment are applied by the Company prospectively.

Where an item of property and equipment comprises major components with different useful lives, the components are accounted for as separate items of property and equipment. Expenditures incurred to replace a component of an item of property and equipment that is accounted for separately, including major inspection and overhaul expenditures are capitalized.

3.3 Taxation

Income tax expense represents the sum of current income tax expense and deferred income tax expense. Current income tax expense is based on taxable income for the period. Income tax is recognized in the statement of loss and comprehensive loss except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity.

Current income tax is the expected income tax payable or receivable on the taxable income or loss for the period, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous periods.

Deferred income tax assets and liabilities are recognized based on differences in the financial statement carrying amount for assets and liabilities and the associated tax balance. Deferred income tax liabilities are generally recognized for all taxable temporary differences. Temporary differences are not provided for goodwill not deductible for tax purposes, the initial recognition of assets or liabilities that affect neither accounting nor taxable loss and differences relating to investments in subsidiaries to the extent that they will probably not reverse in the foreseeable future. The amount of deferred income tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the statement of financial position date. Deferred income tax assets are generally recognized for all deductible temporary differences, unused tax credits carried forward and unused tax losses to the extent that it is probable that there will be taxable income against which deductible temporary differences can be utilized.

Deferred income tax assets and liabilities are offset when there is a legally enforceable right to offset current income tax assets against current income tax liabilities, when they relate to income taxes levied by the same taxation authority and when the Company intends to settle its current income tax assets and liabilities on a net basis.

Notes to Consolidated Financial Statements

For the years ended December 31, 2023 and 2022 (Expressed in Canadian Dollars)

3.4 Financial instruments

a) Classification of financial assets and financial liabilities

The Company uses three classification categories for financial assets: measured at amortized cost, fair value through other comprehensive income ("FVTOCI"), and fair value through profit or loss ("FVTPL"). The classification of financial assets is generally based on the business model in which a financial asset is managed and its contractual cash flow characteristics. Financial liabilities are classified and measured in two categories: amortized cost or FVTPL. The Company does not separate derivatives embedded in contracts where the host is a financial asset. Instead, the hybrid financial instruments as a whole are assessed for classification.

The Company's financial assets and financial liabilities are classified as follows:

Cash	Amortized cost
Accounts receivable	Amortized cost
Accounts payable and accrued liabilities	Amortized cost
Loan payable	Amortized cost

On initial recognition, a financial asset is classified as measured at amortized costs, FVTPL, or FVTOCI. Financial assets are not reclassified subsequent to their initial recognition unless the Company changes its business model for managing assets, in which case all affected financial assets are reclassified on the first day of the first reporting period following the change in the business model. The Company recognizes trade receivables initially when they are originated. All other financial assets are initially recognized when the Company becomes a party to the contractual provisions of the instrument. All trade receivables without a significant financing component are initially measured at their transaction prices as defined in IFRS 15. All other financial assets are initially measured at fair value plus, for items not classified as FVTPL, transaction costs that are directly attributable to its acquisition.

Subsequent to initial recognition, financial assets as amortized costs are measured at cost using the effective interest method. The amortized cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognized in profit of loss. Any gain or loss on derecognition is recognized in profit or loss.

All financial liabilities are initially recorded at fair value and designated upon inception as FVTPL or other financial liabilities. All other financial liabilities are initially recognized when the Company becomes a party to the contractual provisions of the instrument.

Classification

Notes to Consolidated Financial Statements

For the years ended December 31, 2023 and 2022 (Expressed in Canadian Dollars)

Financial liabilities classified as other financial liabilities are initially recognized at fair value less directly attributable transaction costs. After initial recognition, other financial liabilities are subsequently measured at amortized cost using the effective interest method. The effective interest method is a method of calculating the amortized cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments through the expected life of the financial liability or, where appropriate, a shorter period.

Financial liabilities classified as FVTPL include financial liabilities held for trading and financial liabilities designated upon initial recognition as FVTPL. Transaction costs on financial liabilities classified as FVTPL are expensed as incurred. Fair value changes on financial liabilities classified as FVTPL are recognized through the statement of comprehensive income/(loss). At the end of each reporting period subsequent to initial recognition, financial liabilities at FVTPL are measured at fair value, with changes in fair value recognized directly in the statement of comprehensive loss in the period in which they arise.

b) Impairment of financial assets

The Company uses a forward-looking "expected credit loss" ("ECL") model. The ECL model requires judgement, including consideration of how changes in economic factors affect ECLs, which will be determined on a probability-weighted basis. The new impairment model is applied, at each reporting date, to the Company's financial assets measured at amortized cost. Impairment losses are recorded in profit or loss with the carrying amount of the financial asset reduced through the use of impairment allowance.

Evidence of impairment may include indications that the counterparty debtor or a group of debtors is experiencing significant financial difficulty, default or delinquency in interest or principal payments, the probability that they will enter bankruptcy or other financial reorganization and where observable data indicates that there is a measurable decrease in the estimated future cash flows, such as changes in arrears or economic conditions that correlate with defaults. Receivables are reviewed qualitatively on a case-by-case basis to determine whether they need to be written off.

Expected credit losses are measured as the difference in the present value of the contractual cash flows that are due to the Company under the contract, and the cash flows that the Company expects to receive. The Company assesses all information available, including past due status, credit ratings, the existence of third-party insurance, and forward-looking macro-economic factors in the measurement of the expected credit losses associated with its assets carried at amortized cost.

Financial assets are written off when there is no reasonable expectation of recovery.

Notes to Consolidated Financial Statements

For the years ended December 31, 2023 and 2022 (Expressed in Canadian Dollars)

c) Derecognition

The Company derecognizes financial assets only when the contractual rights to cash flows from the financial assets expire, or when it transfers the financial assets and substantially all of the associated risks and rewards of ownership to another entity. Gains and losses on derecognition are recognized in profit or loss. The Company derecognizes financial liabilities only when its obligations under the financial liabilities are discharged, cancelled or expired. Generally, the difference between the carrying amount of the financial liability derecognized and the consideration paid and payable, including any non-cash assets transferred or liabilities assumed, is recognized in profit or loss.

3.5 Impairment of non-financial assets

At each date of the statements of financial position, the Company reviews the carrying amounts of its tangible and intangible assets to determine whether there is an indication that those assets have suffered an impairment loss. If any such indication exists, or when annual impairment testing for an asset is required, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the Company estimates the recoverable amount of the cash generating unit to which the assets belong.

The recoverable amount is the higher of fair value less costs to sell and value in use. In assessing the value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used. These calculations are corroborated by valuation multiples, quoted share prices for publicly traded companies or other available fair value indicators.

If the recoverable amount of an asset (or cash generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash generating unit) is reduced to its recoverable amount. An impairment loss is recognized immediately in the statement of comprehensive loss, unless the relevant asset is carried at a re-valued amount, in which case the impairment loss is treated as a revaluation decrease.

Where an impairment loss subsequently reverses, the carrying amount of the asset (cash generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognized for the asset (or cash generating unit) in prior periods. A previously recognized impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognized.

Notes to Consolidated Financial Statements

For the years ended December 31, 2023 and 2022 (Expressed in Canadian Dollars)

3.6 Significant accounting judgments and estimates

The preparation of these consolidated financial statements in conformity with IFRS requires management to make estimates and judgments that affect the applications of accounting policies regarding certain types of assets, liabilities, revenues, and expenses in the preparation of these consolidated financial statements. Estimates and judgments are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the year in which the estimates are revised and in any future years affected. These estimates and judgments are based on management's historical experience, best knowledge of current events or conditions and activities that the Company may undertake in the future. Actual results could differ materially from these estimates.

Judgments

Information about critical judgments in applying accounting policies that have the most significant risk of causing material adjustment to the amounts reported in these consolidated financial statements are discussed below:

a) Business combinations, control and significant influence

The Company uses judgment in determining the entities that it controls and therefore, consolidates or has significant influence over and therefore accounts for on an equity basis. The Company controls an entity when the Company has existing rights that give it the current ability to direct the activities that significantly affect the entities' returns. The Company has significant influence when the Company has the power to participate in the financial and operating policy decisions of the investee, but does not control nor has joint control of that investee's policies.

b) Intangible assets and goodwill

Management is required to use judgment in determining the economic useful lives of identifiable intangible assets. Judgment is also required to determine the frequency with which these assets are to be tested for impairment. The Company uses judgment in determining the grouping of assets to identify its Cash Generating Units ("CGUs") for purposes of testing for impairment of intangible assets and goodwill. In testing for impairment, goodwill acquired in a business combination is allocated to the CGUs that are expected to benefit from the synergies of the business combination. In testing for impairment of intangibles with indefinite lives, these assets are allocated to the CGUs to which they relate.

c) Income taxes

In calculating current and deferred income taxes, the Company uses judgment when interpreting the tax rules where the Company operates. The Company also uses judgment in classifying transactions and assessing probable outcomes of claimed or accrued deductions, which considers expectations of future operating results, the timing and reversal of temporary differences and possible audits of income tax filings by tax authorities.

Notes to Consolidated Financial Statements

For the years ended December 31, 2023 and 2022 (Expressed in Canadian Dollars)

Estimates

The effect of a change in an accounting estimate is recognized prospectively by including it in profit or loss in the year of the change, if the change affects that year only, or in the year of the change and future years, if the changes affects both.

a) Fair value of intangible assets and goodwill

With respect to intangible assets acquired and goodwill recognized in a business combination, the Company determines fair values using such estimates such as discounts rates, growth rates and terminal capitalization rates. These estimates take into account any material change to the assumptions that occur when reviewed annually by management.

3.7 Inventory

Inventories comprise of health supplements manufactured by NatureVan and TonyMoly branded skincare products purchased by Triniti, and other materials held by Justera. These items are stated at the lower of cost and net realizable value. The inventory costs are determined using the specific identification basis.

Net realizable value for the inventory is generally considered to be the selling price in the ordinary course of business less the estimated costs of completion and the estimated costs to make the sale.

3.8 Foreign currency translation

In preparing the financial statements, transactions in currencies other than the entity's functional currency are translated at the rates of exchange prevailing at the dates of the transactions. At the end of each reporting period, monetary assets and liabilities denominated in foreign currencies are translated at the exchange rates prevailing at that date. Exchange gains and losses are recognized on a net basis in the statement of loss and comprehensive loss.

3.9 Share capital

Common shares are classified as equity. Incremental costs directly attributable to the issue of common shares and units are recognized as a deduction from equity.

The Company records proceeds from share issuances net of issue costs and any tax effects.

Notes to Consolidated Financial Statements

For the years ended December 31, 2023 and 2022 (Expressed in Canadian Dollars)

3.10 Provisions

Provisions are recognized when the Company has a present obligation (legal or constructive) that has arisen as a result of a past event and it is probable that a future outflow of resources will be required to settle the obligation, provided that a reliable estimate can be made of the amount of the obligation. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risk specific to the obligation. The increase in the provision due to passage of time is recognized as interest expense.

3.11 Revenue

The Company uses a five step model for recognizing revenue from contracts with customers. The standard requires revenue to be recognized in a manner that depicts the transfer of promised goods or services to a customer and at an amount that reflects the expected consideration receivable in exchange for transferring those goods or services. This is achieved by applying the following five steps:

- 1. Identify the contract with a customer;
- 2. Identify the performance obligations in the contract;
- 3. Determine the transaction price;
- 4. Allocate the transaction price to the performance obligations in the contract; and
- 5. Recognize revenue when (or as) the entity satisfies a performance obligation.

IFRS 15 also provides guidance relating to the treatment of contract acquisition and contract fulfillment costs.

Services provided to customers

The Company provides skincare services to customers. Under IFRS 15, the total consideration for service contracts is allocated based on their stand-alone selling prices, and revenue is recognized over time as performance obligations are satisfied.

3.12 Operating segments

The Company determines its reportable segments based on, among other things, how the chief operating decision makers, including the Chief Executive Officer, regularly reviews its operations and performance.

For the years ended December 31, 2023 and 2022, management has determined that the Company operated in one operating and reportable segments being the health and wellness industry.

Notes to Consolidated Financial Statements

For the years ended December 31, 2023 and 2022 (Expressed in Canadian Dollars)

3.13 Leases

The Company leases buildings, primarily for office use. For all lease contracts entered into, or changed, the Company recognizes a right-of-use asset and a lease liability at the lease commencement date.

The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, less any lease incentive received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. There are no dismantling, removal and restoration costs included in the cost of the right-of-use asset as management has not incurred an obligation for those costs.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's incremental borrowing rate. The lease liability is measured at amortized cost using the effective interest rate method.

3.14 Intangible assets

Intangible assets acquired through asset acquisitions or business combinations are initially recognized at fair value. Intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives. The Company evaluates the reasonableness of the estimated useful lives of these intangible assets on an annual basis. The Company reviews intangible assets with indefinite lives annually for impairment but impairment may be reviewed earlier if circumstances indicate that the carrying amount may not be recoverable. Indefinite life intangible assets are not amortized.

The estimated useful lives of intangible assets are as follows:

Developed technologies 2 years
Brand 10 years
Customer relationships 10 years

3.15 Goodwill

Goodwill represents the excess purchase price over the fair value of identifiable assets acquired less liabilities assumed from business combinations. Goodwill is not amortized. The Company reviews goodwill annually for impairment but impairment may be reviewed earlier if circumstances indicate that the carrying amount may not be recoverable.

Notes to Consolidated Financial Statements

For the years ended December 31, 2023 and 2022 (Expressed in Canadian Dollars)

3.16 Warrants

Proceeds received on the issuance of units, consisting of common shares and warrants, are allocated first to common shares based on the market trading price of the common shares at the time the units are priced, and any excess is allocated to warrants.

Broker warrants and other share purchase warrants issued for goods or services are measured at fair value using the Black-Scholes option pricing model.

3.17 Earnings (loss) per share

The Company presents basic and diluted earnings (loss) per share for its common shares, calculated by dividing the earnings (loss) attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the period. Diluted earnings per share is determined by adjusting the earnings attributable to common shareholders and the weighted average number of common shares outstanding for the effects of all dilutive potential common shares. Diluted loss per share is equivalent to basic loss per share, as the effects of all dilutive potential common shares would be anti-dilutive.

3.18 Future accounting standards

The Company continues to review changes to IFRS standards. There are no other pending IFRSs or IFRIC interpretations that are expected to be relevant to the Company's consolidated financial statements.

4. INVENTORY

	As at December 31, 2023	As at December 31, 2022
	\$	\$
Covid-19 test kits under laboratory testing	-	301,711
Justera – finished goods	10,000	-
NatureVan – finished goods	43,396	160,368
Triniti – finished goods	44,547	-
	97,943	462,079

The cost of inventory included in the cost of sales was \$317,238 (2022 - \$3,757,962).

Notes to Consolidated Financial Statements

For the years ended December 31, 2023 and 2022 (Expressed in Canadian Dollars)

5. PROPERTY AND EQUIPMENT

	COVID	Other		Leasehold	
	Equipment	Equipment	Vehicles	improvements	Total
	\$	\$	\$	\$	\$
Cost:					
As at December 31, 2021	1,038,166	_	231,771	_	1,269,937
Additions	117,778	_	_	_	117,778
As at December 31, 2022	1,155,944	_	231,771	_	1,387,715
Additions		145,071	_	125,000	270,071
Disposals	(1,155,944)	_	(37,970)	_	(1,193,914)
Impairment		(63,891)		(125,000)	(188,891)
As at December 31, 2023	_	81,180	193,801	_	274,981
Accumulated depreciation:					
As at December 31, 2021	311,503	_	72,213	_	383,716
Depreciation	385,314	_	112,445	_	497,759
As at December 31, 2022	696,817	_	184,658	_	881,475
Depreciation	233,257	10,307	42,040	_	285,604
Disposals	(930,074)	_	(32,897)	_	(962,971)
Impairment	<u> </u>	(4,674)		_	(4,674)
As at December 31, 2023		5,633	193,801		199,434
Net book value:					
As at December 31, 2022	459,127	_	47,113		506,240
As at December 31, 2023		75,547		_	75,547

During the year ended December 31, 2023, the Company sold equipment with a carrying value of \$225,870 for proceeds of \$349,851 for a gain of \$123,981.

During the year ended December 31, 2023, the Company sold vehicle with a carrying value of \$5,073 for proceeds of \$20,000 for a gain of \$14,927.

Notes to Consolidated Financial Statements

For the years ended December 31, 2023 and 2022 (Expressed in Canadian Dollars)

6. INTANGIBLE ASSETS AND GOODWILL

	Developed		Customer		
	technologies	Brand	relationships	Goodwill	Total
	\$	\$		\$	\$
Cost:					
As at December 31, 2021	2,117,600	_	_	602,165	2,719,765
Additions [note 12]	635,000	_	_	2,073,833	2,708,833
As at December 31, 2022	2,752,600	_	_	2,675,998	5,428,598
Additions [note 12]	_	122,689	204,177	520,283	847,149
Impairment	(635,000)	(55,638)	(92,592)	(3,196,281)	(3,979,511)
As at December 31, 2023	2,117,600	67,051	111,585	_	2,296,236
Accumulated depreciation:					
As at December 31, 2021	1,624,460	_	_	_	1,624,460
Depreciation	546,056	_	_	_	546,056
As at December 31, 2022	2,170,516	_	_	_	2,170,516
Impairment	(52,916)	_	_	_	(52,916)
As at December 31, 2023	2,117,600	_			2,117,600
Net book value:					
As at December 31, 2022	582,084			2,675,998	3,258,082
As at December 31, 2023	_	67,051	111,585	_	178,636

Notes to Consolidated Financial Statements

For the years ended December 31, 2023 and 2022 (Expressed in Canadian Dollars)

7. RELATED PARTY TRANSACTIONS

Related parties are defined as management and principal shareholders of the Company and/or members of their immediate family and/or other companies and/or entities in which a principal shareholder, director or senior officer is a principal owner or senior executive. Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company, including directors, advisory board members, officers of the Company.

Related party transactions, with entity with common management and shareholders, are as follows:

	For the year ended December 31, 2023	For the year ended December 31, 2022
Salaries paid to current and former officers and directors	289,083	638,333
Consulting fees paid to current and former officers and directors	523,293	663,500
Rent paid to a company controlled by a former director	15,400	60,900
Share-based payments	47,755	-

Included in accounts receivable as at December 31, 2023 are \$359,452 (2022 - \$Nil) receivable from current and former officers and directors of the Company.

Included in accounts payable and accrued liabilities as at December 31, 2023 are \$377,580 (2022 - \$Nil) payable to current and former officers and directors of the Company.

8. RIGHT-OF-USE ASSET AND LEASE LIABILITIES

During the thirteen months ended December 31, 2021, the Company entered into a lease agreement with a company controlled by a former director of the Company. The lease contract contained a deposit in the amount of \$10,000 that will be applied for the rent of the last two months the lease term. The lease was terminated in December 2023, and the deposit of \$10,000 was included in general and administrative expenses during the year ended December 31, 2023.

During the year ended December 31, 2022, the Company entered into a lease agreement with an arm's length party for NatureVan. The lease was for \$2,300 per month that was terminated in June 2023.

During the year ended December 31, 2023, NatureVan entered into a lease agreement with an arm's length party for NatureVan. The lease commenced on August 1, 2023, expiring on July 31, 2026, with an option to renew for an additional 5 years. The lease is for 850 sq. ft. with an initial rent of \$2,479 per month until July 31, 2024, increasing by \$1 per sq. ft. at each anniversary. The lease was terminated in November 2023.

During the year ended December 31, 2023, the Company entered into a lease agreement with an arm's length party for NatureVan. The lease commenced on May 15, 2023, expiring on May 14, 2026, with an option to renew for an additional 3 years. The lease is for 517 sq. ft. with an initial rent of \$4,093 per month until May 14, 2024, increasing by \$5 per sq. ft. at each anniversary.

Notes to Consolidated Financial Statements

For the years ended December 31, 2023 and 2022 (Expressed in Canadian Dollars)

Upon completion of the acquisition of Triniti, the Company assumed the lease that ended on December 31, 2023. The Company elected to renew the lease until December 31, 2026. The lease payment is \$5,852 per month until December 31, 2025, increasing to \$5,904 per month for the last year ending December 31, 2026.

Right-of-use asset

	\$
Balance at December 31, 2021	119,929
Addition	62,720
Amortization charge for the year	(63,185)
Balance at December 31, 2022	119,464
Addition	390,716
Amortization charge for the year	(108,262)
Terminated	(128,847)
Impaired	(103,827)
Balance at December 31, 2023	169,244

Lease liability

·	\$
Balance at December 31, 2021	120,829
Addition	62,720
Accretion on lease liability	16,415
Lease payments	(79,300)
Balance at December 31, 2022	120,664
Addition	390,716
Accretion on lease liability	17,080
Lease payments	(124,557)
Terminated	(129,503)
Balance at December 31, 2023	274,400
Classified as current	85,350

When measuring the lease liability, the Company discounted lease payments using its incremental borrowing rate of 12% to 15%.

Future lease payments are as follows:

Classified as non-current

Year ended December 31, 2024	\$70,224
Year ended December 31, 2025	\$70,224
Year ended December 31, 2026	\$70,851

189,050

Notes to Consolidated Financial Statements

For the years ended December 31, 2023 and 2022 (Expressed in Canadian Dollars)

9. SHARE CAPITAL

a) Authorized:

Unlimited number of common shares, one vote per share, without par value.

b) Issued:

On February 22, 2022, the Company acquired AddBio and issued 33,000,000 common shares valued at \$2,475,000 (note 12).

On May 1, 2022, the Company acquired NatureVan and issued 25,833,331 common shares valued at \$1,420,833 (note 12).

On December 14, 2022, the Company issued 9,700,000 units at \$0.05 per unit for gross proceeds of \$485,000. Each unit consisted of one common share and one share purchase warrant exercisable at \$0.05 for 18 months from the date of issuance. The Company paid finder's fees of \$1,200.

On December 14, 2022, the Company issued 8,600,000 common shares at \$0.05 per share for gross proceeds of \$430,000.

On July 24, 2023, the Company acquired Juillet Wellness Spa and issued 4,000,000 common shares valued at \$120,000 (note 12). As at December 31, 2023, a total of 4,000,000 common shares were held in escrow by the Company's legal counsel.

On October 14, 2023, the Company issued 33,973,336 common shares at \$0.03 per share for gross proceeds of \$1,019,200. The Company paid finder's fees of \$33,672 and other share issue costs of \$29,280.

On November 14, 2023, the Company acquired Triniti and issued 4,060,000 common shares valued at \$101,500 (note 12).

Options

The Company adopted an Omnibus Incentive Plan (the "Plan") whereby the Company may, from time to time, grant stock options or restricted share units, to certain directors, officers, employees and/or consultants of the Company. The maximum number of common shares reserved for issue pursuant to the Plan shall not exceed, in the aggregate, 10% of the number of common shares then outstanding.

In January 2023, the Company granted 4,800,000 stock options to certain officers, directors and consultants of the Company exercisable at \$0.05 per share expiring on January 26, 2025. The fair value of these options was \$67,416 calculated using the Black-Scholes Option Pricing Model using the following assumptions: expected life: 2 years, expected volatility: 180.57%, expected dividend yield: Nil, and risk-free rate: 3.57%.

Notes to Consolidated Financial Statements

For the years ended December 31, 2023 and 2022 (Expressed in Canadian Dollars)

During the year ended December 31, 2023, a total of 300,000 options were forfeited due to resignation of an officer and, as at December 31, 2023, a total of 4,500,000 options remained outstanding and exercisable.

Warrants

The changes in the Company's warrants for the years ended December 31, 2023 and 2022 are as follows:

	Number of warrants	Weighted average exercise price
Balance, December 31, 2021	2,205,754	\$1.40
AddBio acquisition (note 12)	33,000,000	\$0.15
NatureVan acquisition (note 12)	25,833,331	\$0.07
GoStop warrants expired	(2,000,000)	\$1.50
Issued from a private placement	9,700,000	\$0.05
Expired	(74,080)	\$0.20
Balance, December 31, 2022	68,665,005	\$0.11
Expired	(131,674)	\$0.30
Balance, December 31, 2023	68,533,331	\$0.11

As at December 31, 2023, the Company had the following warrants outstanding and exercisable:

Number of warrants	Exercise price	Expiry date
33,000,000	\$0.15	March 18, 2024
25,833,331	\$0.07	May 13, 2024
9,700,000	\$0.05	June 14, 2024

10. FINANCIAL RISK FACTORS

Fair Value

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either in the principal market for the asset or liability or in the absence of a principal market, in the most advantageous market for the asset or liability. The principal or the most advantageous market must be accessible by the Company.

Notes to Consolidated Financial Statements

For the years ended December 31, 2023 and 2022 (Expressed in Canadian Dollars)

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits from the asset's highest and best use or by selling it to another market participant that would utilize the asset in its highest and best use.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy. This is described, as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 inputs are quoted prices in active markets for identical assets or liabilities at the measurement date.
- Level 2 inputs are observable inputs other than quoted prices included within Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable directly or indirectly.
- Level 3 inputs are unobservable inputs for the asset or liability that reflect the reporting entity's own assumptions and are not based on observable market data.

Unless otherwise noted, the carrying value of cash, accounts receivable, accounts payable and accrued liabilities approximates fair value for each financial instrument.

Financial Risk Management

The Company is exposed to credit risk and liquidity risk. The Company's management oversees the management of these risks. The Company's management is supported by the Board that advises on financial risks and the appropriate financial risk governance framework for the Company. The Company's financial risk activities are governed by appropriate policies and procedures and that financial risks are identified, measured and managed in accordance with Company policies and the Company risk appetite.

(a) Credit Risk

Credit risk is the risk of unexpected loss if a customer or third party to a financial instrument fails to meet its contractual obligations. Financial instruments which potentially subject the Company to concentrations of credit risk consist of cash and accounts receivable. The cash consists of money held in a reputable Canadian bank. To reduce its credit risk from its accounts receivable, the Company reviews credit history of new clients before extending credit. Historically, there has been no collection issue with any of the Company's customers.

Notes to Consolidated Financial Statements

For the years ended December 31, 2023 and 2022 (Expressed in Canadian Dollars)

(b) Liquidity Risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting obligations associated with financial liabilities. The Company is exposed to this risk mainly in respect of its accounts payable and accrued liabilities. The Company's approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. The Company manages liquidity risk through obtaining financing from its shareholders. At December 31, 2023, the Company had a working capital deficiency of \$575,751 (2022 – deficiency of \$2,566,902) and, as a result, the Company will need additional financing in the future.

11. CAPITAL MANAGEMENT

The Company's objectives when managing capital are to maintain a strong capital base so as to maintain investor, creditor and market confidence and sustain future development of the business. The capital of the Company consists of equity.

The Company manages its capital structure and makes adjustments in light of the changes in its economic environment and the risk characteristics of the Company's assets. To effectively manage the Company's capital requirements, the Company has in place planning, budgeting and forecasting process to help determine the funds required to ensure the Company has the appropriate liquidity to meet its operating and growth objectives. There were no externally imposed capital requirements to which the Company is subject as at December 31, 2023.

12. ACQUISTIONS

Add Biomedical Inc.

In February 2022, the Company announced a proposed acquisition of Add Biomedical Inc., a biomedical screening company with the initial focus on breast cancer detection. In March 2022, the Company completed the acquisition of all of the issued and outstanding shares of Add Bio. Pursuant to the Share Purchase Agreement, the Company issued 33,000,000 units of the Company (note 9), each unit consisting of one common share and one common share purchase warrant. Each warrant exercisable to purchase one common share at an exercise price of \$0.15 per share for 24 months.

The purchase price had a total fair value of \$3,038,001 calculated as follows: \$2,475,000 related to 33,000,000 common shares of the Company and \$563,001 related to 33,000,000 warrants determined by the Black-Scholes option pricing model using the following assumptions: (i) expected warrant life of 2.00 years; (ii) risk free rate of 1.89%; (iii) dividend yield of nil; and (iv) expected volatility of 75.71%.

The acquisition of AddBio was accounted for as an asset acquisition consistent with IFRS 2 – Shares based payments, as it did not meet the definition of a business under IFRS 3 – Business combination. During the year ended December 31, 2022, the Company recognized an intangible asset in the amount of \$635,000 related to AddBio's developed technology (note 6). The difference of \$1,333,225 calculated as the purchase price of \$3,038,001, less cash acquired from AddBio of \$1,069,776 and the intangible asset of \$635,000, have been recorded as excess consideration included as other expense in the Company's profit or loss.

Notes to Consolidated Financial Statements

For the years ended December 31, 2023 and 2022 (Expressed in Canadian Dollars)

NatureVan Nutrition Ltd.

On May 1, 2022, the Company completed the acquisition of NatureVan, an e-commerce and retail business with natural health supplement products. The acquisition of NatureVan expands the Company's opportunities in the health and wellness industry. The Company issued 25,833,331 units of the Company (note 9), each unit consisting of one common share and one common share purchase warrant. Each warrant exercisable to purchase one common share at an exercise price of \$0.07 per share for 24 months.

The purchase price had a total fair value of \$2,389,682 calculated as follows: \$650,000 paid in cash, \$1,420,833 related to 25,833,331 common shares of the Company and \$318,849 related to 25,833,331 warrants determined by the Black-Scholes option pricing model using the following assumptions: (i) expected warrant life of 2.00 years; (ii) risk free rate of 2.73%; (iii) dividend yield of nil; and (iv) expected volatility of 52.31%.

The acquisition of NatureVan was accounted for as a business combination, in which the assets acquired and the liabilities assumed are recorded at their estimated fair values.

The allocation of the purchase consideration is as follows:

	Amount
Purchase consideration	
Cash	\$ 650,000
Common shares	1,420,833
Warrants	318,849
Total	\$ 2,389,682
Fair value of assets acquired and liabilities assumed	
Cash	163,314
Accounts receivable and other receivables	7,096
Inventory	149,074
Prepaid expenses	2,300
Accounts payable and accrued liabilities	(5,935)
Total identifiable net assets assumed	315,849
Goodwill	2,073,833
Total	\$ 2,389,682

Goodwill recognized comprises the assembled workforce and their knowledge, regulatory affairs and expected revenue growth and future market development.

NatureVan had limited history of operations and, as a result, the Company's pro-forma information presenting the combined results as if the acquisition of NatureVan was completed at the beginning of the period would not be significantly different from these results presented for the year ended December 31, 2022.

Notes to Consolidated Financial Statements

For the years ended December 31, 2023 and 2022 (Expressed in Canadian Dollars)

Juillet Wellness Spa

In July 2023, the Company completed the acquisition of Juillet Wellness Spa ("Juillet"), a full-service wellness centre, providing a wide range of beauty and wellness services, including registered massage therapy, physiotherapy, traditional Chinese medicine through acupuncture, laser hair removal and skincare. The Company issued 4,000,000 common shares of the Company valued at \$120,000 (note 9) and assuming liabilities of \$450,000.

The acquisition of Juillet was accounted for as a business combination, in which the assets acquired and the liabilities assumed are recorded at their estimated fair values.

The allocation of the purchase consideration is as follows:

		Amount
Purchase consideration		
Common shares	\$	120,000
Assumed liabilities		450,000
Total	\$	570,000
Fair value of assets acquired and liabilities assumed		
Furniture and equipment	\$	29,491
Customer relationships	•	204,177
Brand		122,689
Deferred tax liabilities		(88,254)
Total identifiable net assets acquired		268,103
Goodwill		301,897
Total	\$	570,000

Goodwill recognized comprises the assembled workforce and their knowledge, regulatory affairs and expected revenue growth and future market development.

Revenue and net loss of Juillet since the acquisition date included in these consolidated financial statements are \$688,872 and \$116,160, respectively.

The pro-forma revenue and profit or loss of the Company for the year ended December 31, 2023, as though the acquisition of Juillet occurred on January 1, 2023, is not being included in these financial statements since Juillet was operating as a private entity and such disclosure is not readily available without incurring additional costs to the Company.

Notes to Consolidated Financial Statements

For the years ended December 31, 2023 and 2022 (Expressed in Canadian Dollars)

Triniti Trading Corporation (dba TonyMoly)

In November 2023, the Company completed the acquisition of Triniti, a distributor of TonyMoly skincare products. The Company issued 4,060,000 common shares of the Company valued at \$101,500 (note 9) and paid cash of \$125,000.

The acquisition of Triniti was accounted for as a business combination, in which the assets acquired and the liabilities assumed are recorded at their estimated fair values.

The allocation of the purchase consideration is as follows:

	Amount
Purchase consideration	
Cash	\$ 125,000
Common shares	 101,500
Total	\$ 226,500
Fair value of assets acquired and liabilities assumed	
Cash	\$ 899
Inventory	30,000
Security deposits	17,243
Computer and equipment	4,183
Accounts payable and accrued liabilities	(4,211)
Loan payable	(40,000)
Total identifiable net assets acquired	8,114
Goodwill	218,386
Total	\$ 226,500

Goodwill recognized comprises the assembled workforce and their knowledge, regulatory affairs and expected revenue growth and future market development.

Revenue and net loss of Triniti since the acquisition date included in these consolidated financial statements are \$24,562 and \$36,116, respectively.

The pro-forma revenue and profit or loss of the Company for the year ended December 31, 2023, as though the acquisition of Triniti occurred on January 1, 2023, is not being included in these financial statements since Triniti was operating as a private entity and such disclosure is not readily available without incurring additional costs to the Company.

Notes to Consolidated Financial Statements

For the years ended December 31, 2023 and 2022 (Expressed in Canadian Dollars)

Triniti had a loan payable balance of \$40,000 related to the Canada Emergency Business Account ("CEBA") on the date of acquisition. The loan is non-interest bearing and no principal repayments are required up to December 31, 2023. If the principal balance of \$40,000 is repaid by December 31, 2023, then the remaining \$20,000 of the principal balance will be forgiven. The repayment deadline for the loan to qualify for forgiveness of \$20,000 was extended from December 31, 2023 to January 18, 2024. Any remaining balance after January 19, 2024, will be converted into a 2-year term loan with a fixed interest of 5% per annum, monthly interest-only payments and the outstanding balance must be repaid in full by December 31, 2026. Triniti did not repay the principal balance of \$40,000 resulting in the Company recognizing \$20,000 in other expenses to reverse the loan forgiveness during the year ended December 31, 2023.

13. INCOME TAXES

Current income taxes

	For the year ended December 31, 2023	For the year ended December 31, 2022
	\$	\$
Net loss before income taxes	(3,020,496)	(5,251,782)
Tax rate	27%	27%
Income tax recoverable	(815,534)	(1,417,981)
Permanent differences	1,061,294	507,163
Deferred tax liabilities from business combinations	88,254	_
Unrecognized deferred tax assets	(293,992)	910,818
Income tax recovery	40,022	

Deferred income taxes

	For the year ended	For the year ended	
	December 31, 2023	December 31, 2022	
	\$	\$	
Non-capital loss carry forward	987,626	1,395,400	
Property and equipment	380,223	225,640	
Share issue costs	25,996	18,565	
Intangible assets	(48,232)	_	
Deferred tax assets not recognized	(1,345,613)	(1,639,605)	

Notes to Consolidated Financial Statements

For the years ended December 31, 2023 and 2022 (Expressed in Canadian Dollars)

The Company's ability to realize the tax benefits is dependent upon a number of factors, including the history of earnings and the future profitability of operations. Deferred tax assets are recognized only to the extent that it is probable that sufficient taxable profits will be available to allow the asset to be recovered. Accordingly, a corresponding full valuation allowance was recorded to deferred tax assets.

As at December 31, 2023, the Company had non-capital losses amounting to approximately \$3,700,000 and will expire in between 2040 and 2043.

14. CONTINGENCY

A vendor commenced a claim against the Company in the Ontario Small Claims Court claiming damages of \$16,055. The Company has defended the claim. The claim remains outstanding as of December 31, 2023. The dispute is in its early stages and the outcome of the matter is undeterminable at this time.

15. SEGMENT INFORMATION AND MAJOR CUSTOMERS

For the years ended December 31, 2023 and 2022, the Company one operating and reportable segment being health and wellness.

During the year ended December 2023, 53% (2022 – 95%) of the Company's sales was generated by one customer, Datametrex AI Limited ("DM").

During the year ended December 31, 2023, the Company entered into a settlement agreement with DM whereby both parties agreed to adjust the unit sales price for the COVID testings performed in prior years which, in effect, resulted in a gain of \$4,888,625 for the year with an offsetting reduction in accounts payable to DM.

16. SUBSEQUENT EVENT

A total of 1,150,00 stock options were forfeited due to resignations and/or termination of certain directors, officers, employees and/or consultants.